Mon - Fri 09:00-18:00 0207 060 3773
Email info@boundarycapital.com

Month

May 2016
Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance. Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria – both ‘gram positive’ and...
Read More

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases